With nod to fuel-injection technology, this company seeks $86M IPO to send migraine drug up your schnoz

The three-year-old South San Francisco company last month launched a late-stage clinical trial of its self-administered, pre-filled, single-use device delivering a dry-powder migraine drug through the nose.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news